Collection of Blood and Urine From Patients Undergoing Radiation Therapy

StatusEnrolling by Invitation
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 326 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Re-verified, no change to tracked fields
  3. Re-verified, no change to tracked fields
  4. Minor Eligibility criteria expanded, about 5 words
  5. 27 versions Re-verified since Nov 26, 2025, no change to tracked fieldsv296-v322
Show 19 earlier versionsHide 19 earlier versions
  1. Study Status, Eligibilityv295
  2. Re-verified, no change to tracked fieldsv294
  3. Minor Enrollment target: 720 to 1000v293
  4. 16 versions Re-verified since Oct 24, 2024, no change to tracked fieldsv277-v292
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: -Research in NCI's Radiation Oncology Branch depends on the availability of blood and urine samples from patients receiving radiation therapy. Objectives: -To explore the effects of radiation therapy on gene expression in white blood cells, to measure radiation damage in red blood cells and to examine changes in hormone levels in the blood and urine after radiation therapy. Eligibility: -Patients 18 years of age and older who are receiving radiation therapy. Design: * Blood and urine samples are collected when participants enter the study. * Additional samples may be collected at different times during and after treatment. Ideally, samples are obtained before, at the completion of, and 1 month following radiation therapy. Blood samples usually will be collected during routine patient monitoring procedures and will not require an additional needle stick. * A total of 300 patients will be studied at the NCI in Bethesda, MD, Johns Hopkins University in Baltimore and the University of Pennsylvania in Philadelphia.
Trial Details
NCT Number NCT00027326
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)
Carcinoma, Cancer, Tumor
Related terms Carcinoma, Neoplasms
Enrollment 1,000 participants
Start Date
Updated on ClinicalTrials.gov